Effects of granisetron in children undergoing high-dose chemotherapy: A multi-institutional, cross-over study

International Journal of Oncology

Volumn 14, Issue 4, 1999, Pages 673-679

  Tsuchida, Yoshiaki ^a   Hayashi, Yutaka ^b   Asami, Keiko ^c   Yamamoto, Keiko ^d   Yokoyama, Jotaro ^e   Mugishima, Hideo ^f   Honna, Toshiro ^g   Mimaya, Jun'ichi ^h   Hara, Fujio ⁱ   Sawada, Tadashi ^j   Matsumura, Takafumi ^j   Suita, Sachiyo ^k   Sugimoto, Tohru ^l   Kaneko, Michio ^m  

^a Gumna Children S Medical Center   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c Niigata Prefectural Cancer Center   (Japan)

^d SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^e KEIO UNIVERSITY   (Japan)

^f NIHON UNIVERSITY   (Japan)

^g NATIONAL CHILDREN S HOSPITAL   (Japan)

^h SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

ⁱ NAGOYA CITY UNIVERSITY   (Japan)

^j KYOTO PREFECTURAL UNIVERSITY   (Japan)

^k KYUSHU UNIVERSITY   (Japan)

^l UNIVERSITY OF MIYAZAKI   (Japan)

^m UNIVERSITY OF TSUKUBA   (Japan)

more..

Author keywords

Granisetron; High dose chemotherapy; Infants and children; Neuroblastoma; Solid tumors

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; GRANISETRON;

ADOLESCENT; ARTICLE; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; EATING; FEMALE; HUMAN; INFANT; MALE; MULTICENTER STUDY; NEOPLASM; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; EATING; FEMALE; GRANISETRON; HUMANS; INFANT; MALE; NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 18144445731     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.4.673     Document Type: Article

References (18)

1. Iwafuchi M, Utsumi J, Tsuchida Y, Kaneko M, Matsuyama S, Ohnuma N, Taguchi N, Mugishima H, Yokoyama J, Sasaki S, Yoshioka A, Nagahara N, Fukuzawa M and Suita S: Evaluation of patients with advanced neuroblastoma surviving more than 5 years after initiation of an intensive Japanese protocol: a report from the Study Group of Japan for Treatment of Advanced Neuroblastoma. Med Pediatr Oncol 27: 515-520, 1996.
2. Kaneko M, Nishihira H, Mugishima H, Ohnuma N, Nakada K, Kawa K, Fukuzawa M, Suita S, Sera Y and Tsuchida Y: Stratification of treatment of stage 4 neuroblastoma patients based on N-myc amplification status. Med Pediatr Oncol 31: 1-7, 1998.
3. Matthay KK, O'Leary MC, Ramsey NK, Villablanca J, Reynolds CP, Atkinson JB, Haase GM, Stram DO and Seeger RC: Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Eur J Cancer 31A: 572-575, 1995.
4. Haase GM, O'Leary MC, Ramsey NKC, Romansky SG, Stram DO, Seeger RC and Hammond GD: Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma. J Pediatr Surg 26: 1119-1124, 1991.
5. Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa R, Pinketon R, Micon J, Pritchard J, Klingebiel T, Kremens B, Pearson A, Coze C, Paolocci P, Frappaz D, Gadner H and Chauvin F: Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16: 953-956, 1998.
6. Kushner BH, La Quaglia MP, Bonilla MA, Lindsley K, Rosenfield N, Yeh S, Eddy J, Gerald WL, Heller G and Cheung NKV: Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 12: 2607-2613, 1994.
7. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, Heyn R, Jones PM, Lawrence W, Newton W, Ortega J, Raney RB, Ruymann FB, Teft M, Webber B, Wiener E, Wharam M, Vietti TJ and Maurer HM: The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13: 610-630, 1995.
8. Von Schweinitz D, Hecker H, Harms D, Bode U, Weinel P, Bürger D, Erttmann R and Mildenberger H: Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB-89. J Pediatr Surg 30: 845-852, 1995.
9. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM and Tattersall MNH: On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer 19: 203-208, 1983.
10. Joss RA, Brand BC, Buser KS and Cerny T: The symptomatic control of cytostatic drug-induced emesis: a recent history and review. Eur J Cancer 26 (Suppl. 1): S2-S8, 1990.
11. Warr D, Wilan A, Venner P, Pater J, Kaizer L, Laberge F, Latreille J, Stewart D, O'Connell G, Osoba D, Wilson K, Davis A and Johnston D: A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphen-hydramine for cisplatin-induced emesis. Eur J Cancer 29A: 33-36, 1993.
12. Chevallier B on behalf of the Granisetron Study Group: Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 26 (Suppl. 1): S33-S36, 1990.
13. Andrews PLR, Rapeport WG and Sanger GJ: Neuropharmacology of emesis induced by anti-cancer therapy. In: TIPS-September. Elsevier Publications, Cambridge, pp334-341, 1988.
14. Kamanabrou D on behalf of the Granisetron Study Group: Intravenous granisetron: establishing the optimal dose. Eur J Cancer 28A (Suppl. 1): S6-S11, 1992.
15. Lemerle J, Amaral D, Southall DP, Upward J and Murdoch RD: Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients. Eur J Cancer 27: 1081-1083, 1991.
16. Fujimoto T, Hirota T, Shimizu H, Oka T, Kikuta A, Mugishima H, Tonouchi T, Koizumi S, Takaue Y and Okamura J: A controlled, dose-comparison study of granisetron for nausea and vomiting induced by cancer chemotherapy in children. Int J Clin Oncol 1: 57-60, 1996.
17. Nakanishi M, Ohsawa J, Nonaka M, Kamiyama J, Idoguchi K, Tabata T, Okuno T and Shinoda M: Comparison of granisetron and the combination of granisetron plus methylpredonisolone in the prophylaxis of cisplatin-induced emesis. Int J Clin Oncol 2: 138-142, 1997.
18. Craft AW, Price L, Eden OB, Shaw P, Cambell R, Pierce DM, Murdoch R and Upward J: Granisetron as antiemetic therapy in children with cancer. Med Pediatr Oncol 25: 28-32, 1995.